Abstract 2066
Background
1L IO mono tx for advanced NSCLC is an option based on recent clinical trials. As there are few data regarding tx sequencing following 1L IO mono tx for NSCLC, there is interest in seeking evidence to identify optimal tx sequences in this setting. This analysis explored 2L systemic tx and overall survival (OS) in pts with NSCLC following 1L IO mono tx in a real-world setting.
Methods
A retrospective analysis of 2604 randomly selected pts with advanced (stage IIIB/IV) NSCLC treated in US practices (156 community and 3 academic sites) between Jan 2013 and Dec 2018 was conducted using the Flatiron Health EHR-derived database. Tx regimens were defined using only therapies initiated in the first 30 days of tx. 1L tx was defined as tx received prior to disease progression (PD); 2L tx was defined as first tx after first PD. 2L tx patterns and OS were assessed in pts treated with 1L IO mono tx. OS and 95% CIs were calculated using Kaplan-Meier (KM) methods.
Results
Pts treated with 1L IO mono tx (initiated after 01 Jan 2016) at each site were identified in the database (N = 105). 91 pts were eligible for the initial exploratory analysis (platinum-based doublet/triplet, n = 35; single-agent chemo, n = 26; IO ± chemo, n = 15; other, n = 15; Table). A multivariable-adjusted KM analysis of 2L OS revealed longer survival with platinum-based doublet/triplet (24.4 months) vs IO ± chemo (17.9 months), other (11.6 months), and single-agent chemo (4.7 months).Table:
1497P Adjusted 2L OS in pts treated with 1L IO mono Tx
Treatment Group | Events/Total, N/N | OS, Median (95% CI), months |
---|---|---|
Platinum-based doublet/triplet | 13/35 | 24.4 (10.6-24.4) |
IO ± cytotoxic chemo | 7/15 | 17.9 (4.9-17.9) |
Othera | 11/15 | 11.6 (5.3-NE) |
Single-agent cytotoxic chemo | 19/26 | 4.7 (3.0-14.7) |
NE, not estimable.
aIncludes targeted mono tx/doublets, chemo/monoclonal antibody doublets, chemo doublets, and clinical study drugs.
Conclusions
Although the longest survival was in the platinum-based cohort, the unknown tx strategy for 1L IO mono tx and a small sample size limit the generalizability of the data. The hypothesis-generating result suggests further research on the efficacy of 2L platinum therapy after 1L IO tx is needed. Additional analyses of complementary real-world data in an NSCLC population treated with IO in the 1L are planned.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Celgene.
Disclosure
S.M. Fish: Full / Part-time employment: Celgene. T. Jin Ong: Full / Part-time employment: Celgene. E.D. Flick: Full / Part-time employment: Celgene. D.M. Waterhouse: Advisory / Consultancy: AbbVie; Advisory / Consultancy: Amgen; Advisory / Consultancy: AZ; Advisory / Consultancy: BMS. All other authors have declared no conflicts of interest.
Resources from the same session
1613 - Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: initial Phase 1b results
Presenter: David Berz
Session: Poster Display session 1
Resources:
Abstract
2853 - Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
Presenter: Petros Christopoulos
Session: Poster Display session 1
Resources:
Abstract
1974 - A Phase II Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients with Activating Epidermal Growth Factor Receptor mutation (EGFRm) from Circulating Tumor DNA (CtDNA)
Presenter: Young-Chul Kim
Session: Poster Display session 1
Resources:
Abstract
3370 - Influence of cow’s milk on the absorption and exposure of erlotinib in NSCLC patients
Presenter: Geerten Veerman
Session: Poster Display session 1
Resources:
Abstract
5900 - PTEN loss as Predictor of Tumor Heterogeneity (TH) and Poor Prognosis in EGFR-mutant Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients (pts) Receiving Tyrosine-Kinase Inhibitors (TKIs).
Presenter: Miriam Ferrara
Session: Poster Display session 1
Resources:
Abstract
1302 - Safety of lorlatinib in subgroups of patients from a phase 1/2 trial
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
1497 - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase 2 ALTA trial
Presenter: Dae Ho Lee
Session: Poster Display session 1
Resources:
Abstract
2349 - The safety assessment of crizotinib and alectinib from real world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).
Presenter: Kei Kunimasa
Session: Poster Display session 1
Resources:
Abstract
1120 - Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the Use Via Expanded Access to Brigatinib (UVEA-Brig) study
Presenter: Silvia Novello
Session: Poster Display session 1
Resources:
Abstract
5239 - Treatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice
Presenter: Matthew Krebs
Session: Poster Display session 1
Resources:
Abstract